Title : Subcutaneous interferon β-1a three times weekly and the natural evolution of gadolinium-enhancing lesions into chronic black holes in relapsing and progressive multiple sclerosis: Analysis of PRISMS and SPECTRIMS trials.

Pub. Date : 2017 Oct-Dec

PMID : 29276624






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Objective: The objective of this paper is to assess the effect of IFN beta-1a and placebo on CBH evolution and disability in patients with relapsing-remitting multiple sclerosis (RRMS), as well as CBH evolution in patients with secondary progressive multiple sclerosis (SPMS). S-(D-CARBOXYBUTYL)-L-HOMOCYSTEINE interferon alpha 1 Homo sapiens
2 Results: In RRMS patients, the risk of >=1 evolved CBH was lower for IFN beta-1a versus placebo (odds ratio 0.42; p = 0.024); volume of newly evolved CBH was numerically reduced. S-(D-CARBOXYBUTYL)-L-HOMOCYSTEINE interferon alpha 1 Homo sapiens
3 Conclusion: In RRMS, IFN beta-1a significantly decreased the proportion of new T1 Gd+ lesions evolving into CBH and the risk of developing a CBH. S-(D-CARBOXYBUTYL)-L-HOMOCYSTEINE interferon beta 1 Homo sapiens
4 Conclusion: In RRMS, IFN beta-1a significantly decreased the proportion of new T1 Gd+ lesions evolving into CBH and the risk of developing a CBH. S-(D-CARBOXYBUTYL)-L-HOMOCYSTEINE interferon beta 1 Homo sapiens